The safety and efficacy of psilocybin therapy in patients with cancer and major depressive disorder. - Manish Agrawal; Paul Thambi; Sarah Shnayder (Journal of Clinical Oncology, 2022)

Spatiotemporal Mapping of Online Interest in Cannabis and Popular Psychedelics before and during the COVID-19 Pandemic in Poland. - Al-Imam A; Motyka MA; Witulska Z; Younus M; Michalak M (International journal of environmental research and public health, 2022)

Unique Effects of Sedatives, Dissociatives, Psychedelics, Stimulants, and Cannabinoids on Episodic Memory: A Review and Reanalysis of Acute Drug Effects on Recollection, Familiarity, and Metamemory - Doss MK; Samaha J; Barrett FS; Griffiths RR; de Wit H; Gallo DA; Koen JD. (bioRxiv, 2022)

Psilocybin-Assisted Therapy Found to Improve Depression, Offer Other Benefits - Richard Karel (Psychiatric News, 2022)

An Overview on the Taxonomy, Phylogenetics and Ecology of the Psychedelic Genera Psilocybe, Panaeolus, Pluteus and Gymnopilus - Dominique Strauss; Soumya Ghosh; Zurika Murray; Marieka Gryzenhout (Frontiers in Forests and Global Change, 2022)

New Paradigms of Old Psychedelics in Schizophrenia. - Mahmood D; Alenezi SK; Anwar MJ; Azam F; Qureshi KA; Jaremko M (Pharmaceuticals (Basel, Switzerland), 2022)

Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant Depression - National Institute of Mental Health; Czech Republic (ClinicalTrials.gov, 2022)

Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence. - Edinoff AN; Fort JM; Singh C; Wagner SE; Rodriguez JR; Johnson CA; Cornett EM; Murnane KS; Kaye AM; Kaye AD (Neurology international, 2022)

Psilocybin-induced takotsubo cardiomyopathy. - Kotts WJ; Gamble DT; Dawson DK; Connor D (BMJ case reports, 2022)

The Efficacy of Psilocybin in the Treatment of Depression andAnxiety: A Meta-Analysis - Andrew Hodge; Suporn Sukpraprut-Braaten; Robert Strayhan (Current Psychiatry Research and Reviews, 2022)

Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy. - Mocanu V; Mackay L; Christie D; Argento E (Substance abuse treatment, prevention, and policy, 2022)

Grounded in Biology: Why the Context-Dependency of Psychedelic Drug Effects Means Opportunities, Not Problems for Anthropology and Pharmacology - Stephan Schleim (Frontiers in Psychiatry, 2022)

A critique of: Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds - Carhart-Harris R; Daws RE; Nutt D. (PsyArXiv, 2022)

A critique of: Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds - Robin Carhart-Harris; Richard E Daws; David Nutt (PsyArXiv, 2022)

The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol. - Johansen L; Liknaitzky P; Nedeljkovic M; Mastin-Purcell L; Murray G (Systematic reviews, 2022)

Receptor binding profiles and behavioral effects of psilocybin analogs - Grant C. Glatfelter; David R. Manke; Andrew R. Chadayne; Michael H. Baumann (The FASEB Journal, 2022)

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. - Holze F; Ley L; Müller F; Becker AM; Straumann I; Vizeli P; Kuehne SS; Roder MA; Duthaler U; Kolaczynska KE; Varghese N; Eckert A; et al. (Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 2022)

The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice. - Stein CA; Penn A; Van Hope S; Dorsen CG; Mangini M (Journal of midwifery & women's health, 2022)

Psychoactive Drugs in the Management of Post Traumatic Stress Disorder: A Promising New Horizon. - Elsouri KN; Kalhori S; Colunge D; Grabarczyk G; Hanna G; Carrasco C; Aleman Espino A; Francisco A; Borosky B; Bekheit B; Ighanifard M; Astudillo AA; et al. (Cureus, 2022)

Unraveling the Mysteries of Mental Illness With Psilocybin. - Sotille R; Singh H; Weisman A; Vida T (Cureus, 2022)

Socio-psychedelic imaginaries: envisioning and building legal psychedelic worlds in the United States - Claudia Schwarz-Plaschg (European Journal of Futures Research, 2022)

Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy in Major Depression - University of Zurich (ClinicalTrials.gov, 2022)

Sex-Specific Effects of Psychedelic Drug Exposure on Central Amygdala Reactivity and Behavioral Responding - Effinger D; Quadir S; Ramage M; Cone M; Herman M. (bioRxiv, 2022)

Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds - Doss M; Barrett FS; Corlett PR. (PsyArXiv, 2022)

Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds - Manoj Doss; Frederick Streeter Barrett; Philip R. Corlett (PsyArXiv, 2022)

P388. Open Label Psilocybin Administration in Severely Treatment Resistant Depression - Scott Aaronson; Tammy Miller; Samuel Rudow; MacKenzie Forbes; Trisha Suppes (Biological Psychiatry, 2022)

P450. Pilot Study Evaluation of Psilocybin Therapy for Anorexia Nervosa: Safety, Acceptability, and Preliminary Efficacy - Stéphanie Knatz Peck; Samatha Shao; Susan Murray; Walter H. Kaye (Biological Psychiatry, 2022)

Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel-Mediated Cardiotoxicity. - Hackl B; Todt H; Kubista H; Hilber K; Koenig X (The international journal of neuropsychopharmacology, 2022)

Models of psychedelic drug action: modulation of cortical-subcortical circuits. - Doss MK; Madden MB; Gaddis A; Nebel MB; Griffiths RR; Mathur BN; Barrett FS (Brain: a journal of neurology, 2022)

Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders. - Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W (Molecules (Basel, Switzerland), 2022)

Combining FTIR-ATR and OPLS-DA methods for magic mushrooms discrimination - Cátia Esteves; Elena M. M. de Redrojo; José Luis Manjón; Gabriel Moreno; Filipe E. Antunes; Gemma Montalvo; Fernando E. Ortega-Ojeda (Forensic Chemistry, 2022)

Charismatic, Synchronous and Psychedelic Religious Experiences: A Personal Account - Brian Macallan (Religions, 2022)

Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample. - Jones G; Ricard JA; Lipson J; Nock MK (Scientific reports, 2022)

Production and extraction of psilocybin and psilocin from Psilocybe spp. mushrooms - Costa Fernandes Joana Margarida; Filho Cesar; Machado Brito-da-Costa Andreia; Marin-Bruzos Marieta; Saayman Jean; Sanders Daniel; Dinis-Oliveira Ricardo Jorge (RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia, 2022)

Evaluation of a quantitative analytical method for psilocin and psilocybin using HPLC-DAD - Filho Cesar; Costa Fernandes Joana Margarida; Machado Brito-da-Costa Andreia; Marin-Bruzos Marieta; Saayman Jean; Sanders Daniel; Dinis-Oliveira Ricardo Jorge (RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia, 2022)

Psylocybin and Psilocin as new tools to fight depression: an overview of the Pharmacodynamic and pharmacokinetic mechanisms - Lemos Martins Sofia; Machado Brito-da-Costa Andreia; Madureira-Carvalho Áurea; Dinis-Oliveira Ricardo Jorge; Dias da Silva Diana (RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia, 2022)

Psilocybe mexicana R. Heim - Mexikanischer Kahlkopf - Antonia Kuhn; Matthias F. Melzig (Zeitschrift für Phytotherapie, 2022)

Verbal behavior related to drug reinforcement in polysubstance cannabis users: Comparison across drugs. - Cox DJ; Johnson MW (Experimental and clinical psychopharmacology, 2022)

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. - Becker AM; Holze F; Grandinetti T; Klaiber A; Toedtli VE; Kolaczynska KE; Duthaler U; Varghese N; Eckert A; Grünblatt E; Liechti ME (Clinical pharmacology and therapeutics, 2022)

Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development. - Van Court RC; Wiseman MS; Meyer KW; Ballhorn DJ; Amses KR; Slot JC; Dentinger BTM; Garibay-Orijel R; Uehling JK (Fungal biology, 2022)

Increased global integration in the brain after psilocybin therapy for depression. - Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R (Nature medicine, 2022)

Neuroimaging Documentation of Psychedelic Drugs Effect on the Brain: DMT, LSD, Psilocybin, and Ibogaine as Examples: A Mini Review - Abdulwahab F. Alahmari (International Journal of Neurobiology, 2022)

Demystifying Psychedelic Treatments in Psychiatry: Is Ego Dissolution the Solution? - Michael Avissar; Adrian Jacques H. Ambrose (Psychiatric News, 2022)

Shared and distinct brain regions targeted for immediate early gene expression by ketamine and psilocybin - Davoudian PA; Shao L; Kwan AC. (bioRxiv, 2022)

Counselors’ attitudes toward psychedelics and their use in therapy - Benjamin Hearn; Michael D. Brubaker; George B. Richardson (Journal of Counseling & Development, 2022)

The mushroom, the frog, and the rainbow of desire: A participatory-psychedelic spiritual emergence. - Lahood G. (The International Journal of Transpersonal Studies, 2022)

Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history. - Pearson C; Siegel J; Gold JA (Journal of the neurological sciences, 2022)

Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain. - Meade E; Hehir S; Rowan N; Garvey M (Journal of fungi (Basel, Switzerland), 2022)

184. Hallucinogens on TikTok - Amrutha Garimella; Bradley Kerr; Reese H. Hyzer; Megan A. Moreno (Journal of Adolescent Health, 2022)

Psilocybin Combines Rapid Synaptogenic And Anti-Inflammatory Effects In Vitro - Smedfors G; Glotfelty E; Kalani N; Hjelle CP; Horntvedt O; Wellfelt K; Brodin A; von Kieseritzky F; Olson L; Karlsson T. (Research Square, 2022)

Rediscovering psychedelics - Bethany Halford﻿ (C&EN Global Enterprise, 2022)

Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity - Gaddis A; Lidstone DE; Nebel MB; Griffiths R; Mostofsky SH; Mejia A; Barrett F. (bioRxiv, 2022)

Persisting decreases in state and trait anxiety post-psilocybin: A naturalistic, observational study among retreat attendees - Kiraga M; Kuypers KPC; Uthaug MV; Ramaekers J; Mason NL. (medRxiv, 2022)

[Rapid-acting antidepressants-neurobiological mechanisms of action]. - Gass P; Vasilescu AN; Inta D (Der Nervenarzt, 2022)

Beating pain with psychedelics: Matter over mind? - Elman I; Pustilnik A; Borsook D (Neuroscience and biobehavioral reviews, 2022)

[Are psychedelics fast acting antidepressant agents?]. - Gründer G; Brand M; Kärtner L; Scharf D; Schmitz C; Spangemacher M; Mertens LJ (Der Nervenarzt, 2022)

Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. - Schlag AK; Aday J; Salam I; Neill JC; Nutt DJ (Journal of psychopharmacology (Oxford, England), 2022)

The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs' effects on psychological flexibility. - Wolff M; Mertens LJ; Walter M; Enge S; Evens R (Journal of psychopharmacology (Oxford, England), 2022)

Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer. - Bates N; Bello JK; Osazuwa-Peters N; Sullivan MD; Scherrer JF (Current treatment options in oncology, 2022)

Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice - Thomas Christopher W.; Blanco-Duque Cristina; Bréant Benjamin J.; Goodwin Guy M.; Sharp Trevor; Bannerman David M.; Vyazovskiy Vladyslav V. (Translational Psychiatry, 2022)

Natural language signatures of psilocybin microdosing - Sanz C; Cavanna F; Muller S; de la Fuente L; Zamberlan F; Palmucci M; Janeckova L; Kuchar M; Carrillo F; García AM; Pallavicini C; Tagliazucchi E. (bioRxiv, 2022)

Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study. - Jones GM; Nock MK (Scientific reports, 2022)

Increased low-frequency brain responses to music after psilocybin therapy for depression - Wall MB; Lam C; Ertl N; Kaelen M; Roseman L; Nutt DJ; Carhart-Harris RL. (bioRxiv, 2022)

Psilocybin: Characterization of the Metastable Zone Width (MSZW), Control of Anhydrous Polymorphs, and Particle Size Distribution (PSD). - Kargbo RB; Sherwood AM; Meisenheimer P; Lenoch K; Abebe S (ACS omega, 2022)

A Randomized Controlled Trial of the Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion - NYU Langone Health (ClinicalTrials.gov, 2022)

Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis. - Yu CL; Liang CS; Yang FC; Tu YK; Hsu CW; Carvalho AF; Stubbs B; Thompson T; Tsai CK; Yeh TC; Yang SN; Shin JI; et al. (Journal of clinical medicine, 2022)

Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective? - Coppola M; Bevione F; Mondola R (Journal of xenobiotics, 2022)

Hallucinogen chemistry guides antidepressant drug discovery - Bethany Halford﻿ (C&EN Global Enterprise, 2022)

Genomic Analysis of Reveals Its Nutritional Strategy and Application Potential in Bioremediation. - Yang Y; Meng G; Ni S; Zhang H; Dong C (Journal of fungi (Basel, Switzerland), 2022)

Hallucinogen Use and Misuse in Older Adults. - Redden WM; Paracha SU; Sheheryar Q (Clinics in geriatric medicine, 2022)

Analysis of recreational psychedelic substance use experiences classified by substance. - Hase A; Erdmann M; Limbach V; Hasler G (Psychopharmacology, 2022)

Crystallographic hallucinations. - Toby BH (Acta crystallographica. Section C, Structural chemistry, 2022)

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. - Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR (Journal of psychopharmacology (Oxford, England), 2022)

Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine. - Averill LA; Abdallah CG (Expert opinion on investigational drugs, 2022)

Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review. - Ziff S; Stern B; Lewis G; Majeed M; Gorantla VR (Cureus, 2022)

Structure-based discovery of nonhallucinogenic psychedelic analogs. - Cao D; Yu J; Wang H; Luo Z; Liu X; He L; Qi J; Fan L; Tang L; Chen Z; Li J; Cheng J; et al. (Science (New York, N.Y.), 2022)

Psychedelics hold promise for primary care research - James Bailey Sanford (Family Practice, 2022)

Psilocybine vergeleken met escitalopram bij depressie - Jurriaan F. M. Strous (Pure Amsterdam UMC, 2022)

[Psilocybin compared with escitalopram for depression]. - Strous JFM (Nederlands tijdschrift voor geneeskunde, 2022)

Pennsylvania bill seeks clinical research on psychedelics - Valerie A. Canady (Mental Health Weekly, 2022)

Classic psychedelics in the treatment of depression: mechanisms of action and the role of therapy - Ellen Saikku (Työväentutkimus Vuosikirja, 2022)

Acute psilocybin and ketanserin effects on cerebral blood flow: 5-HT2AR neuromodulatory effects in healthy humans - Klaus Richter Larsen; Drummond E-Wen McCulloch; Brice Ozenne; Ulrich Lindberg; Sophia Armand; M. Madsen; Dea Siggaard Stenbæk; Gitte M. Knudsen; Patrick M. Fisher (Neuroscience Applied, 2022)

Neurochemical properties of psilocybin in comparison to ketamine in vivo - A. Wojtas; A. Bysiek; Z. Szych; M. Herian; K. Gołembiowska (Neuroscience Applied, 2022)

Differential effects of repeated treatment with DOI and psilocybin on the head-twitch response (HTR), locomotor activity and anxiety-like behaviour - E. Stojek; Jack Prenderville; F. Dunphy-Doherty (Neuroscience Applied, 2022)

Effects of psilocybin in relative and global cerebral blood flow and behavioural correlates - Nathalie M. Rieser; Ladina P Gubser; Franz X. Vollenweider; Meyer Lars; Katrin H. Preller (Neuroscience Applied, 2022)

Neurochemical and behavioural characterisation of the psychedelic 5HT2AR agonist psilocybin in mice - Ines Erkizia-Santamaría; R. Alles-Pascual; Igor Horrillo; Albert Adell; J. Javier Meana; J.E. Ortega (Neuroscience Applied, 2022)

The effect of psilocybin and sleep manipulation on neuroplasticity and sleep architecture in rats - Lucie Olejníková; Klára Šíchová; K. Chona; Hynek Danda; Tomáš Páleníček (Neuroscience Applied, 2022)

The role of psilocybin in memory consolidation in the animal model - K. Šíchová; K. Chona; Lucie Olejníková Ladislavová; T. Páleníček (Neuroscience Applied, 2022)

Acute change in functional brain entropy following psilocybin administration in healthy volunteers - Drummond E-Wen McCulloch; Anders Smærup Olsen; Dea Siggaard Stenbæk; Sophia Armand; M.K. Madsen; Gitte M. Knudsen; Patrick M. Fisher (Neuroscience Applied, 2022)

Investigation of the neural network responsible for antidepressant effect of serotonergic psychedelics - Daisuke Ibi (Proceedings for Annual Meeting of The Japanese Pharmacological Society, 2022)

SPECIAL ISSUE: Do Biofeedback, Neurofeedback, and Neuromeditation Have a Role in Psychedelic-Assisted Therapies? - Jeff Tarrant (Biofeedback, 2022)

Exploratory review of psilocybin usage and awareness amongst college students and potential consumer goods tradeoffs resulting from increased usage - Russell J. Zwanka (International Journal of Research in Marketing Management and Sales, 2022)

Investigation of neuronal basis underlying antidepressant effect of serotonergic psychedelics - Daisuke Ibi (Proceedings for Annual Meeting of The Japanese Pharmacological Society, 2022)

Comparison of subjective, autonomic, and endocrine effects of LSD and psilocybin in healthy subjects - Friederike Holze; Laura Ley; F. Müller; V. Nimmy; Anne Eckert; Matthias E. Liechti (Neuroscience Applied, 2022)

Investigating cue-reactivity as biomarker for treatment success in psilocybin-assisted therapy for alcohol use disorder - Nathalie M. Rieser; Ladina P Gubser; C. Rossgoderer Da Silva; Franz X. Vollenweider; Marcus Herdener; Katrin H. Preller (Neuroscience Applied, 2022)

The efficacy of COMP360 psilocybin therapy in treatment-resistant depression: exploratory results from a phase IIb randomised controlled trial - G. Goodwin; Scott T. Aaronson; Boadie W. Dunlop; D. Feifel; David J. Hellerstein; L. Marwood; S. Mistry; Metten Somers; S.C. Stansfield; J. Tsai; S. Williams; Allan H. Young; et al. (Neuroscience Applied, 2022)

Psychedelic Agents as Potential Therapeutics for Obsessive Compulsive Disorder - Josh Nagra (DOAJ (DOAJ: Directory of Open Access Journals), 2022)

Raising awareness: The implementation of medical cannabis and psychedelics used as an adjunct to standard therapy in the treatment of advanced metastatic breast cancer - Rayyan Zafar; Dustin Sulak; Jaime Brambila; David Nutt; Anne Katrin Schlag (Drug Science Policy and Law, 2022)

The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a phase IIb randomised controlled trial - G.M. Goodwin; Scott T. Aaronson; Boadie W. Dunlop; David Feifel; David J. Hellerstein; N. Hewitt; L. Marwood; S. Mistry; Metten Somers; S.C. Stansfield; J. Tsai; S. Williams; et al. (Neuroscience Applied, 2022)

Pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of oral psilocybin administration in healthy subjects - Friederike Holze; A. Becker; Karolina E. Kolaczynska; Urs Duthaler; Matthias E. Liechti (Neuroscience Applied, 2022)

Selling the Priceless Mushroom: A History of Psilocybin Mushroom Trade in the Sierra Mazateca (Oaxaca) - Marcos Garcia de Teresa (Journal of Illicit Economies and Development, 2022)

Standards Without Labs: Drug Development in the Psychedelic Underground - John Bailey; Joanna Kempner (Citizen Science Theory and Practice, 2022)

An Interpretative Phenomenological Analysis of the use of psilocybin by veterans with symptoms of trauma - F. N. Smith; Joanna C. Neill; Verity Wainwright (Drug Science Policy and Law, 2022)

Should Adolescents be Included in Emerging Psychedelic Research? - Khaleel Rajwani (Canadian Journal of Bioethics, 2022)

Psychedelic use predicts objective knowledge about climate change via increases in nature relatedness - Christina Sagioglou; Matthias Forstmann (Drug Science Policy and Law, 2022)

Rats hallucinate in a similar manner to humans after psilocin - Vejmola Č.; Syrová K.; Šíchová K.; Vlastimil K.; Klučková T.; Kelemen E.; Páleníček T. (Neuroscience Applied, 2022)

Unravelling a New Conformer of Psilocin Through Computational Methods - Bhadoria Poonam; Venkatnarayan Ramanathan (SSRN Electronic Journal, 2022)

Psychedelic philanthropy: The nonprofit sector and Timothy Leary's 1960s psychedelic movement. - Elcock C (Journal of the history of the behavioral sciences, 2022)

Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention. - Petranker R; Anderson T; Maier LJ; Barratt MJ; Ferris JA; Winstock AR (Journal of psychopharmacology (Oxford, England), 2022)

Psychedelics and health behaviour change. - Teixeira PJ; Johnson MW; Timmermann C; Watts R; Erritzoe D; Douglass H; Kettner H; Carhart-Harris RL (Journal of psychopharmacology (Oxford, England), 2022)

Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals. - McCulloch DE; Madsen MK; Stenbæk DS; Kristiansen S; Ozenne B; Jensen PS; Knudsen GM; Fisher PM (Journal of psychopharmacology (Oxford, England), 2022)

Exploring the Use of Psilocybin Therapy for Existential Distress: A Qualitative Study of Palliative Care Provider Perceptions. - Mayer CE; LeBaron VT; Acquaviva KD (Journal of psychoactive drugs, 2022)

Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis. - Leger RF; Unterwald EM (Journal of psychopharmacology (Oxford, England), 2022)

Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. - Li NX; Hu YR; Chen WN; Zhang B (Journal of affective disorders, 2022)

United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020. - Barnett BS; Parker SE; Weleff J (The International journal on drug policy, 2022)

Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms. - Garcia-Romeu A; Darcy S; Jackson H; White T; Rosenberg P (Current topics in behavioral neurosciences, 2022)

Dosing Psychedelics and MDMA. - Liechti ME; Holze F (Current topics in behavioral neurosciences, 2022)

Psilocybin for the Treatment of Obsessive-Compulsive Disorders. - Ehrmann K; Allen JJB; Moreno FA (Current topics in behavioral neurosciences, 2022)

Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. - Ling S; Ceban F; Lui LMW; Lee Y; Teopiz KM; Rodrigues NB; Lipsitz O; Gill H; Subramaniapillai M; Mansur RB; Lin K; Ho R; et al. (CNS drugs, 2022)

Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach. - Agin-Liebes G; Davis AK (Current topics in behavioral neurosciences, 2022)

Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review. - Schimmers N; Breeksema JJ; Smith-Apeldoorn SY; Veraart J; van den Brink W; Schoevers RA (Psychopharmacology, 2022)

Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets. - Sousa TR; Rema J; Machado S; Novais F (Current topics in medicinal chemistry, 2022)

Psychedelic medicines for mood disorders: current evidence and clinical considerations. - Sarris J; Pinzon Rubiano D; Day K; Galvão-Coelho NL; Perkins D (Current opinion in psychiatry, 2022)

Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action. - Rieser NM; Herdener M; Preller KH (Current topics in behavioral neurosciences, 2022)

Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study. - Marschall J; Fejer G; Lempe P; Prochazkova L; Kuchar M; Hajkova K; van Elk M (Journal of psychopharmacology (Oxford, England), 2022)

The Potential of Psychedelics for End of Life and Palliative Care. - Yaden DB; Nayak SM; Gukasyan N; Anderson BT; Griffiths RR (Current topics in behavioral neurosciences, 2022)

Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples. - Sherwood AM; Kargbo RB; Kaylo KW; Cozzi NV; Meisenheimer P; Kaduk JA (Acta crystallographica. Section C, Structural chemistry, 2022)

MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. - Jones GM; Nock MK (Journal of psychopharmacology (Oxford, England), 2022)

Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. - Jones GM; Nock MK (Journal of psychopharmacology (Oxford, England), 2022)

The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. - Rucker JJ; Marwood L; Ajantaival RJ; Bird C; Eriksson H; Harrison J; Lennard-Jones M; Mistry S; Saldarini F; Stansfield S; Tai SJ; Williams S; et al. (Journal of psychopharmacology (Oxford, England), 2022)

Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension. - Jones GM; Nock MK (Journal of psychopharmacology (Oxford, England), 2022)

Human behavioral pharmacology of psychedelics. - Strickland JC; Johnson MW (Advances in pharmacology (San Diego, Calif.), 2022)

Psilocybin Conspectus: Status, Production Methods, and Considerations. - Plotnik L; Gibbs G; Graham T (International journal of medicinal mushrooms, 2022)

Psychedelics in the Treatment of Headache and Chronic Pain Disorders. - Schindler EAD (Current topics in behavioral neurosciences, 2022)

Psychedelics and Anti-inflammatory Activity in Animal Models. - Flanagan TW; Nichols CD (Current topics in behavioral neurosciences, 2022)

Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation. - Johnson MW (Current topics in behavioral neurosciences, 2022)

Psilocybin for Trauma-Related Disorders. - Khan AJ; Bradley E; O'Donovan A; Woolley J (Current topics in behavioral neurosciences, 2022)

[A Novel System for Discovering High-affinity Antibody Mutants That Enables Immunoassays with Higher Sensitivities -Development and Application of Clonal Array Profiling (CAP)]. - Kiguchi Y (Yakugaku zasshi: Journal of the Pharmaceutical Society of Japan, 2022)

Multi-locus identification of by high-resolution melting (HRM). - Zhang X; Yu H; Wang Z; Yang Q; Xia R; Qu Y; Tao R; Shi Y; Xiang P; Zhang S; Li C (Forensic sciences research, 2022)

Psychedelic Identity Shift: A Critical Approach to Set And Setting. - Devenot N; Seale-Feldman A; Smith E; Noorani T; Garcia-Romeu A; Johnson MW (Kennedy Institute of Ethics journal, 2022)

Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy. - Sekula AD; Downey L; Puspanathan P (Frontiers in psychology, 2022)

Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - Rationale and study design. - Mertens LJ; Koslowski M; Betzler F; Evens R; Gilles M; Jungaberle A; Jungaberle H; Majić T; Ströhle A; Wolff M; Wellek S; Gründer G (Neuroscience applied, 2022)

Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report. - McCulloch DE; Grzywacz MZ; Madsen MK; Jensen PS; Ozenne B; Armand S; Knudsen GM; Fisher PM; Stenbæk DS (Frontiers in pharmacology, 2022)

Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States. - Raison CL; Jain R; Penn AD; Cole SP; Jain S (Frontiers in psychiatry, 2022)

Phenomenological assessment of psychedelics induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI). - Dworatzyk K; Jansen T; Schmidt TT (PloS one, 2022)

Corrigendum: Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes. - Matzopoulos R; Morlock R; Morlock A; Lerer B; Lerer L (Frontiers in psychiatry, 2022)

Race, Ethnic, and Sex Differences in Prevalence of and Trends in Hallucinogen Consumption Among Lifetime Users in the United States Between 2015 and 2019. - Davis AK; Arterberry BJ; Xin Y; Agin-Liebes G; Schwarting C; Williams MT (Frontiers in epidemiology, 2022)

Psilocybin-Assisted Compassion Focused Therapy for Depression. - Pots W; Chakhssi F (Frontiers in psychology, 2022)

Will psilocybin lose its magic in the clinical setting? - Hayes C; Wahba M; Watson S (Therapeutic advances in psychopharmacology, 2022)

Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity. - Huang J; Pham M; Panenka WJ; Honer WG; Barr AM (Frontiers in psychiatry, 2022)

Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default. - Yaden DB; Earp D; Graziosi M; Friedman-Wheeler D; Luoma JB; Johnson MW (Frontiers in psychology, 2022)

The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences. - Frymann T; Whitney S; Yaden DB; Lipson J (Frontiers in psychology, 2022)

Produces Amino Acids to Stimulate Protein Synthesis in Ruminal Tissue Explants the Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta-Serine/Threonine Kinase-Mammalian Target of Rapamycin Complex 1 Pathway. - Wang Q; Ren Y; Cui Y; Gao B; Zhang H; Jiang Q; Loor JJ; Deng Z; Xu C (Frontiers in veterinary science, 2022)

Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders. - Vorobyeva N; Kozlova AA (Frontiers in pharmacology, 2022)

Self-administration of Psilocybin in the Setting of Treatment-resistant Depression. - Lyons A (Innovations in clinical neuroscience, 2022)

Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees. - Kiraga MK; Kuypers KPC; Uthaug MV; Ramaekers JG; Mason NL (Frontiers in psychiatry, 2022)

Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review. - Ko K; Knight G; Rucker JJ; Cleare AJ (Frontiers in psychiatry, 2022)

Editorial: Psychedelic sociality: Pharmacological and extrapharmacological perspectives. - Roseman L; Preller KH; Fotiou E; Winkelman MJ (Frontiers in pharmacology, 2022)

Neuroimaging Correlates of Treatment Response with Psychedelics in Major Depressive Disorder: A Systematic Review. - Kuburi S; Di Passa AM; Tassone VK; Mahmood R; Lalovic A; Ladha KS; Dunlop K; Rizvi S; Demchenko I; Bhat V (Chronic stress (Thousand Oaks, Calif.), 2022)

Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying. - Sweeney MM; Nayak S; Hurwitz ES; Mitchell LN; Swift TC; Griffiths RR (PloS one, 2022)

﻿ (Inocybaceae), a new poisonous species from Eurasia, based on morphological, ecological, molecular and biochemical evidence. - Yan YY; Zhang YZ; Vauras J; Zhao LN; Fan YG; Li HJ; Xu F (MycoKeys, 2022)

Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States. - Davis AK; Agin-Liebes G; España M; Pilecki B; Luoma J (Journal of psychoactive drugs, 2022)

Comment and Response: (Lugo-Radillo & Cortez-Lopez, 2020) Long-Term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-Containing Mushrooms. - Fitzpatrick CM; Anderson BT; Agin-Liebes G; Guydish J (Journal of psychoactive drugs, 2022)

Effects of classic psychedelic drugs on turbulent signatures in brain dynamics. - Cruzat J; Perl YS; Escrichs A; Vohryzek J; Timmermann C; Roseman L; Luppi AI; Ibañez A; Nutt D; Carhart-Harris R; Tagliazucchi E; Deco G; et al. (Network neuroscience (Cambridge, Mass.), 2022)

3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs. - López-Arnau R; Camarasa J; Carbó ML; Nadal-Gratacós N; Puigseslloses P; Espinosa-Velasco M; Urquizu E; Escubedo E; Pubill D (Frontiers in psychiatry, 2022)

Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals. - Søndergaard A; Madsen MK; Ozenne B; Armand S; Knudsen GM; Fisher PM; Stenbæk DS (Frontiers in psychology, 2022)

A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy. - Sottile RJ; Vida T (Frontiers in psychiatry, 2022)

Electrical spiking of psilocybin fungi. - Gandia A; Adamatzky A (Communicative & integrative biology, 2022)

Five new species of from China: Morphological characteristics, phylogenetic analyses, and toxin detection. - Li SN; Xu F; Long P; Liu F; Zhang P; Fan YG; Chen ZH (Frontiers in microbiology, 2022)

Exploring the Credibility of Psilocybin-assisted Therapy and Cognitive-behavioral Therapy for Depression. - Altman BR; Earleywine M; De Leo J (Journal of psychoactive drugs, 2022)

A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap. - Ledwos N; Rosenblat JD; Blumberger DM; Castle DJ; McIntyre RS; Mulsant BH; Husain MI (Journal of clinical psychopharmacology, 2022)

Are Magic Mushrooms Really Magic?: Psilocybin in the Treatment of Depression. - Balon R (Journal of clinical psychopharmacology, 2022)

[Treatment-resistant depression. From classification to new therapies.]. - Paganin W; Signorini S; Leccese V; Sciarretta A (Rivista di psichiatria, 2022)

Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives. - Messell C; Summer L; Bonde LO; Beck BD; Stenbæk DS (Frontiers in psychology, 2022)

Classic psychedelics, health behavior, and physical health. - Simonsson O; Hendricks PS; Chambers R; Osika W; Goldberg SB (Therapeutic advances in psychopharmacology, 2022)

Therapeutic use of psilocybin: Practical considerations for dosing and administration. - MacCallum CA; Lo LA; Pistawka CA; Deol JK (Frontiers in psychiatry, 2022)

Lower-dose psycholytic therapy - A neglected approach. - Passie T; Guss J; Krähenmann R (Frontiers in psychiatry, 2022)

The economics of psychedelic-assisted therapies: A research agenda. - Marseille E; Bertozzi S; Kahn JG (Frontiers in psychiatry, 2022)

"A sense of the bigger picture:" A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use. - DellaCrosse M; Pleet M; Morton E; Ashtari A; Sakai K; Woolley J; Michalak E (PloS one, 2022)

Editorial: Old and new psychoactive substances: Pharmacology and potential applications. - Mayer FP; Luethi D; Areal LB; Sitte HH (Frontiers in psychiatry, 2022)

Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice. - Alper K; Cange J; Sah R; Schreiber-Gregory D; Sershen H; Vinod KY (Frontiers in pharmacology, 2022)

The association between naturalistic use of psychedelics and co-occurring substance use disorders. - Rabinowitz J; Lev-Ran S; Gross R (Frontiers in psychiatry, 2022)

Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action? - Husain MI; Ledwos N; Fellows E; Baer J; Rosenblat JD; Blumberger DM; Mulsant BH; Castle DJ (Frontiers in psychiatry, 2022)

Critique of the Royal Australian and New Zealand College of Psychiatrists Psychedelic Therapy Clinical Memorandum, Dated May 2020 - Victor Chiruta; Paulina K Zemla; Pixie Miller; Nicola Santarossa; John A Hannan (Journal of Medical and Health Studies, 2021)

Conformational Analysis of Psilocybin: A Computational Approach - Poonam Bhadoria; Manish K. Tripathi; V. Ramanathan (SSRN Electronic Journal, 2021)

LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2021)

Predictors of Psychedelic Experience: A Thematic Analysis - McCartney A; McGovern H; De Foe A. (PsyArXiv, 2021)

Predictors of Psychedelic Experience: A Thematic Analysis - Annie McCartney; Hugh McGovern; Alexander De Foe (PsyArXiv, 2021)

Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies. - Niles H; Fogg C; Kelmendi B; Lazenby M (BMC palliative care, 2021)

A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production. - McKernan K; Kane L; Helbert Y; Zhang L; Houde N; McLaughlin S. (F1000Res, 2021)

Psilocybin modulation of dynamic functional connectivity is associated with plasma psilocin and subjective effects - Olsen AS; Lykkebo-Valløe A; Ozenne B; Madsen MK; Stenbæk DS; Armand S; Mørup M; Ganz M; Knudsen GM; Fisher PM. (medRxiv, 2021)

Double-blind Placebo-controlled Naturalistic Study of Microdosing With Psilocybin: Effects on Brain Activity, Behavior, Cognition, Creativity, and Mental Health - National Council of Scientific; Technical Research; Argentina (ClinicalTrials.gov, 2021)

Effects of Psilocybin in Major Depressive Disorder - Johns Hopkins University (ClinicalTrials.gov, 2021)

A Quantitative and Qualitative Report of Psilocybin Induced Mystical-Type Experiences and Their Relation to Lasting Positive Effects - McCulloch DE; Grzywacz MZ; Madsen MK; Jensen PS; Ozenne B; Armand S; Knudsen GM; Fisher PM; Stenbæk DS. (PsyArXiv, 2021)

A Quantitative and Qualitative Report of Psilocybin Induced Mystical-Type Experiences and Their Relation to Lasting Positive Effects - Drummond E-Wen McCulloch; Maria Zofia Grzywacz; Martin Korsbak Madsen; Peter Steen Jensen; Brice Ozenne; Sophia Armand; Gitte Moos Knudsen; Patrick MacDonald Fisher; Dea Siggard Stenbæk (PsyArXiv, 2021)

Announcement of two special issues: behavioural pharmacology of synaptopathies and psychedelic drugs - Louk J. M. J. Vanderschuren; Paul Willner; Emily M. Jutkiewicz; Bart Ellenbroek (Behavioural Pharmacology, 2021)

Microevidence for microdosing with psilocybin mushrooms: a double-blind placebo-controlled study of subjective effects, behavior, creativity, perception, cognition, and brain activity - Cavanna F; Muller S; de la Fuente LA; Zamberlan F; Palmucci M; Janeckova L; Kuchar M; Pallavicini C; Tagliazucchi E. (bioRxiv, 2021)

P.0593 Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals - Drummond E-Wen McCulloch; M. Madsen; Dea Siggaard Stenbæk; Søren Kristiansen; Brice Ozenne; P.S. Jensen; Gitte M. Knudsen; Patrick M. Fisher (European Neuropsychopharmacology, 2021)

P.0353 Study protocol: psilocybin as a treatment for anorexia nervosa: a pilot study - Hannah Douglass; Meg J. Spriggs; R.J. Park; Tim Read; Jennifer L. Danby; Frederico José Coelho de Magalhães; Kirsty L. Alderton; Adèle Lafrance; Dasha Nicholls; David Erritzøe; David Nutt; Robin Carhart-Harris (European Neuropsychopharmacology, 2021)

P.0421 Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - study design, rationale and current status - Lea J. Mertens; Michael Koslowski; Felix Betzler; Ricarda Evens; Maria Gilles; Andrea Jungaberle; Henrik Jungaberle; Tomislav Majić; Max Wolff; Andreas Ströhle; Stefan Wellek; Gerhard Gründer (European Neuropsychopharmacology, 2021)